

## Did you take Depo-Provera and suffer bone mineral density loss before May 31, 2010? You may be entitled to compensation.

### WHAT IS THIS CLASS ACTION ABOUT?

Ms. Noélia Brito (the "**Representative Plaintiff**") represents a class of individuals in Canada who allege that Pfizer misrepresented the risks associated with the use of Depo-Provera, an injectable form of birth control, by failing to indicate that people who use Depo-Provera may experience significant and possibly irreversible bone mineral density loss that could lead to osteopenia or osteoporosis (the "**Class Action**").

Depo-Provera is still sold in Canada, but its packaging and patient information have been updated to describe this risk.

### WHY IS THIS NOTICE BEING PUBLISHED?

To inform you of two important events:

- (1) a settlement agreement was reached with Pfizer to settle the Class Action (the "**Settlement Agreement**"); and
- (2) it's time to sign up to be notified about making a claim.

### ARE YOU A CLASS MEMBER?

You are a class member if you meet these three conditions:

- (1) you took Depo-Provera before **May 31, 2010**;
- (2) you claim to have suffered a bone mineral density loss (osteopenia or osteoporosis) before **May 31, 2010**; and
- (3) you were a resident of Canada during the time you took Depo Provera.

### WHAT IS THE PROPOSED SETTLEMENT AGREEMENT?

The Representative Plaintiff and Pfizer have agreed to settle the Class Action. Pfizer will pay **\$1,913,750** to the class. If the Quebec Superior Court (the "**Court**") approves the Settlement Agreement, class members who meet the eligibility criteria will receive compensation for osteopenia, osteoporosis, and fragility fractures.

In exchange, the class will give a release to Pfizer for all claims arising from the facts alleged in the Class Action. The proposed settlement is not an admission of liability on the part of Pfizer, nor has there been any finding of liability by the Court against Pfizer.

You may be **eligible for compensation** if you make a claim and meet all of the following conditions:

- (1) you took Depo-Provera for contraceptive purposes;
- (2) you received your last injection of Depo-Provera **before June 30, 2006**;
- (3) you have been diagnosed with bone mineral density loss (osteopenia or osteoporosis); and
- (4) you do not suffer from another risk factor.

The baseline value of each claimant's claim will be based on the severity of the bone mineral density loss and its duration. You can find the eligibility criteria in the FAQ at [www.depoprovera.ca](http://www.depoprovera.ca).

The final value of the compensation that will be paid to eligible claimants for their bone mineral density loss and, if applicable, their fractures will depend on the total value of eligible claims. The final value of the compensation will not be determined until the end of the claim period.

### WHEN WILL THE SETTLEMENT AGREEMENT AND THE CLASS COUNSEL LEGAL FEES BE APPROVED?

To become effective, the Settlement Agreement must be approved by the Court. In order to approve the Settlement Agreement, the Court must conclude that it is fair, reasonable and in the best interests of class members.

The Representative Plaintiff will also ask the Court to approve the legal fees of the lawyers representing the class, which are 25% of the amount to be paid to the class by Pfizer, as well as applicable disbursements and taxes.

A hearing on these issues will be held on October 26, 2021, at 1 Notre Dame Street East, Montreal, Quebec. It will be possible to attend the approval hearing by videoconference. Visit [www.depoprovera.ca](http://www.depoprovera.ca) to get up-to-date information on the exact time of the hearing and how to attend.

**If you are satisfied with the Settlement Agreement and want to participate, you can register now to be notified when it's time to make a claim by visiting [www.depoprovera.ca](http://www.depoprovera.ca).**

### WHAT CAN YOU DO IF YOU WANT TO OBJECT?

**Class members can object to the proposed Settlement Agreement or to legal fees.** To object, you must send a written objection to Belleau Lapointe at [info@belleaulapointe.com](mailto:info@belleaulapointe.com) and explain why you believe the Court should not approve the Settlement Agreement or the legal fees. Written objections should not be sent directly to the Court. Class Counsel will file all objections with the Court.

The deadline to submit an objection is October 16, 2021. You can also attend the hearing to make oral submissions about the Settlement Agreement or the legal fees.

**You cannot opt out of the Class Action.** The opt-out period for the Class Action ended on May 31, 2010. Class members will be bound by the Settlement Agreement if it is approved by the Court.

### WHERE CAN YOU GET MORE INFORMATION?

**This notice contains a summary of relevant information about the proposed Settlement Agreement and the legal fees.** For more information, please visit [www.depoprovera.ca](http://www.depoprovera.ca) or contact Class Counsel: Siskinds LLP and Belleau Lapointe, s.e.n.c.r.l. For English inquiries, call Siskinds at 1-800-461-6166. For French inquiries, call Belleau Lapointe at 1-888-987-6701.

If there is a conflict between this notice and the Settlement Agreement, the terms of the Settlement Agreement shall prevail.